Immunophage Biotech Co., Ltd has successfully completed the first phase of Series B1 financing, securing 200 million RMB. This milestone was announced recently, with ZBJL CAPITAL leading the financing round and InvesTarget acting as the financial advisor.
The funds raised in this financing round will support the Phase II clinical trials of Immunophage's Tier I projects and Phase I clinical trials of Tier II projects. Immunophage is committed to implementing financing strategies ensuring the smooth progression of clinical trials and expediting the introduction of innovative products to the market to benefit patients.
Immunophage boasts a robust pipeline and has filed nearly twenty PCT patents, and some patents have already been granted in countries and regions such as the United States, Europe, Japan, and South Korea. Several projects have gained recognition from multinational pharmaceutical companies and prominent domestic pharmaceutical enterprises. Currently, commercial negotiations are underway, and licensing or cooperative development agreements are anticipated to be reached soon.
